FENC (Fennec Pharmaceuticals) Moat Score: 4/10 (As of Jun. 26, 2026)


FENC Fennec Pharmaceuticals Inc FENC
54 GF Score
Price $11.02
GF Value $9.94
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is Fennec Pharmaceuticals Moat Score?

Fennec Pharmaceuticals FENC +4.45% 54 Moat Score is 4 as of Jun. 26, 2026. GuruFocus rates FENC with a GF Score™ of 54/100 and a GF Value™ of $9.94 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 1,404 Biotechnology companies, Fennec Pharmaceuticals ranks better than 88.82% on this metric.

Fennec Pharmaceuticals has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

Fennec Pharmaceuticals has Narrow Moat: Fennec Pharmaceuticals has a discernible but modest moat due to its focus on niche pharmaceutical products with some intellectual property protection. However, it lacks a broad product portfolio, strong brand strength, and significant regulatory barriers.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Fennec Pharmaceuticals might have Narrow Moat - Discernible but modest moat.

Fennec Pharmaceuticals  (NAS:FENC) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Fennec Pharmaceuticals Moat Score Related Terms

FENC vs VRTX, REGN, ALNY: Moat Score Comparison

For the Biotechnology subindustry, Fennec Pharmaceuticals's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Fennec Pharmaceuticals Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fennec Pharmaceuticals's Moat Score distribution charts can be found below:

* The bar in red indicates where Fennec Pharmaceuticals's Moat Score falls into.


FENC
54GF Score
Fennec Pharmaceuticals Inc FENC
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
Fennec Pharmaceuticals (FENC) has a Moat Score of 4 as of Jun. 26, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Fennec Pharmaceuticals ranks #157 out of 1404 companies in the Biotechnology industry, placing it in the top 11.2%.
Is Fennec Pharmaceuticals' Moat Score too high?
Fennec Pharmaceuticals' current Moat Score is 4. The Biotechnology industry median Moat Score is 2.00. Fennec Pharmaceuticals' value of 4 is 100% above this industry median. Based on the distribution chart, Fennec Pharmaceuticals ranks #157 out of 1404 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Fennec Pharmaceuticals has a GF Score™ of 54/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Fennec Pharmaceuticals' Moat Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Fennec Pharmaceuticals ranks #157 out of 1404 companies for Moat Score. This places Fennec Pharmaceuticals in the top 11% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Fennec Pharmaceuticals' value of 4 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,404 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fennec Pharmaceuticals's current Moat Score of 4 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fennec Pharmaceuticals's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fennec Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Fennec Pharmaceuticals (FENC) is currently considered Modestly Overvalued. The stock's GF Value™ is $9.94, compared to a current price of $11.02 — trading 10.9% above its estimated fair value. The current Moat Score is 4 and 100% above the Biotechnology industry median of 2.00. Fennec Pharmaceuticals' overall GF Score™ is 54/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Fennec Pharmaceuticals (FENC), the current Moat Score is 4 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fennec Pharmaceuticals (FENC) Overvalued in 2026?

Based on GuruFocus' analysis, Fennec Pharmaceuticals stock appears to be overvalued. The current stock price of $11.02 is trading 10.9% above its estimated GF Value™ of $9.94. GuruFocus considers Fennec Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for FENC:

  • Moat Score: 4
  • GF Value™: $9.94 vs. price of $11.02 (10.9% above fair value)
  • GF Score™: 54/100 with 2 warning signs
  • Industry Position: 100% above the Biotechnology median (#157 of 1404)

No single metric tells the full story. See the FENC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Fennec Pharmaceuticals Business Description

Other Exchanges RV41:GermanyFRX:Canada
Address 68 TW Alexander Drive, PO Box 13628, Research Triangle Park, NC, USA, 27709
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
54GF Score

Get the complete analysis for FENC

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$11.02
Price
$9.94
GF Value